BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial ...
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial ...
Source: pr-inside.com
Page 2 - Single Agent News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Single Agent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Single Agent Today - Breaking & Trending Today
Merck Announces Third-Quarter 2023 Financial Results
Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;...
Source: marketscreener.com
BioInvent to Hold Two Poster Presentations at SITC 38th Annual Meeting ...
BioInvent to Hold Two Poster Presentations at SITC 38th Annual Meeting ...
Source: pr-inside.com
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial ...
Source: marketscreener.com
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Source: marketscreener.com